Pfizer ups BIO ante
Pfizer CEO Jeffrey Kindler is elected to the Biotechnology Industry Organization's Board of Directors, replacing Pfizer VP-Corporate Policy and Strategic Management Fred Telling. Retiring from Pfizer this year, Telling has served on the BIO board for eleven years. Pfizer has been working to expand its presence in biotech in recent years (1"The Pink Sheet" Feb. 20, 2006, p. 19)...
You may also be interested in...
Pfizer is emphasizing a diversified approach, focusing on both small molecules and biotech products, as it attempts to regain investor confidence in the company's growth potential
The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.